HPV vaccination and risk of chronic fatigue syndrome/myalgic encephalomyelitis: A nationwide register-based study from Norway

Vaccine

Volumn 35, Issue 33, 2017, Pages 4203-4212

  Feiring, Berit ^a   Laake, Ida ^a   Bakken, Inger Johanne ^a   Greve Isdahl, Margrethe ^a   Wyller, Vegard Bruun ^b   Håberg, Siri E ^a   Magnus, Per ^a   Trogstad, Lill ^a  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b AKERSHUS UNIVERSITY HOSPITAL   (Norway)

Author keywords

Chronic fatigue syndrome; Human papillomavirus vaccine; Medical history; Myalgic encephalomyelitis; Vaccine safety; Vaccine uptake

Indexed keywords

WART VIRUS VACCINE;

ADOLESCENT; ARTICLE; CHILD; CHRONIC FATIGUE SYNDROME; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; NORWAY; PAPILLOMAVIRUS INFECTION; PRIORITY JOURNAL; RISK; RISK ASSESSMENT; VACCINATION; WART VIRUS; CHEMICALLY INDUCED;

ADOLESCENT; CHILD; FATIGUE SYNDROME, CHRONIC; FEMALE; HUMANS; INCIDENCE; MALE; NORWAY; PAPILLOMAVIRUS VACCINES; RISK ASSESSMENT;

EID: 85021066001     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2017.06.031     Document Type: Article

References (67)

1. Prins, J.B., van der Meer, J.W., Bleijenberg, G., Chronic fatigue syndrome. Lancet 367 (2006), 346–355.
2. Lorusso, L., Mikhaylova, S.V., Capelli, E., Ferrari, D., Ngonga, G.K., Ricevuti, G., Immunological aspects of chronic fatigue syndrome. Autoimmun Rev 8 (2009), 287–291.
3. Broderick, G., Fuite, J., Kreitz, A., Vernon, S.D., Klimas, N., Fletcher, M.A., A formal analysis of cytokine networks in chronic fatigue syndrome. Brain, Behav, Immun 24 (2010), 1209–1217.
4. Brenu, E.W., van Driel, M.L., Staines, D.R., Ashton, K.J., Hardcastle, S.L., Keane, J., et al. Longitudinal investigation of natural killer cells and cytokines in chronic fatigue syndrome/myalgic encephalomyelitis. J Trans Med, 10, 2012, 88.
5. Curriu, M., Carrillo, J., Massanella, M., Rigau, J., Alegre, J., Puig, J., et al. Screening NK-, B- and T-cell phenotype and function in patients suffering from chronic fatigue syndrome. J Trans Med, 11, 2013, 68.
6. Sulheim, D., Fagermoen, E., Sivertsen, O.S., Winger, A., Wyller, V.B., Oie, M.G., Cognitive dysfunction in adolescents with chronic fatigue: a cross-sectional study. Arch Dis Childhood 100 (2015), 838–844.
7. Hornig, M., Montoya, J.G., Klimas, N.G., Levine, S., Felsenstein, D., Bateman, L., et al. Distinct plasma immune signatures in ME/CFS are present early in the course of illness. Sci Adv, 1, 2015, e1400121.
8. Wyller, V.B., Reme, S.E., Mollnes, T.E., Chronic fatigue syndrome/myalgic encephalo-myelitis–pathophysiology, diagnosis and treatment. Tidsskr Nor Laegeforen 135 (2015), 2172–2175 [in Norwegian].
9. Ortega-Hernandez, O.D., Shoenfeld, Y., Infection, vaccination, and autoantibodies in chronic fatigue syndrome, cause or coincidence?. Anna New York Acad Sci 1173 (2009), 600–609.
10. Bradley, A.S., Ford, B., Bansal, A.S., Altered functional B cell subset populations in patients with chronic fatigue syndrome compared to healthy controls. Clin Experim Immunol 172 (2013), 73–80.
11. Morris, G., Berk, M., Galecki, P., Maes, M., The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs). Mol Neurobiol 49 (2014), 741–756.
12. Magnus, P., Brubakk, O., Nyland, H., Wold, B.H., Gjessing, H.K., Brandt, I., et al. Vaccination as teenagers against meningococcal disease and the risk of the chronic fatigue syndrome. Vaccine 27 (2009), 23–27.
13. Bakken, I.J., Tveito, K., Aaberg, K.M., Ghaderi, S., Gunnes, N., Trogstad, L., et al. Comorbidities treated in primary care in children with chronic fatigue syndrome/myalgic encephalomyelitis: a nationwide registry linkage study from Norway. BMC Family Pract, 17, 2016, 128.
14. Nguyen, C.B., Alsoe, L., Lindvall, J.M., Sulheim, D., Fagermoen, E., Winger, A., et al. Whole blood gene expression in adolescent chronic fatigue syndrome: an exploratory cross-sectional study suggesting altered B cell differentiation and survival. J Trans Med, 15, 2017, 102.
15. Duclos, P., Safety of immunisation and adverse events following vaccination against hepatitis B. Expert Opin Drug Saf 2 (2003), 225–231.
16. Agmon-Levin, N., Zafrir, Y., Kivity, S., Balofsky, A., Amital, H., Shoenfeld, Y., Chronic fatigue syndrome and fibromyalgia following immunization with the hepatitis B vaccine: another angle of the ‘autoimmune (auto-inflammatory) syndrome induced by adjuvants’ (ASIA). Immunol Res 60 (2014), 376–383.
17. Magnus, P., Gunnes, N., Tveito, K., Bakken, I.J., Ghaderi, S., Stoltenberg, C., et al. Chronic fatigue syndrome/myalgic encephalomyelitis (CFS/ME) is associated with pandemic influenza infection, but not with an adjuvanted pandemic influenza vaccine. Vaccine 33 (2015), 6173–6177.
18. Donegan, K., Beau-Lejdstrom, R., King, B., Seabroke, S., Thomson, A., Bryan, P., Bivalent human papillomavirus vaccine and the risk of fatigue syndromes in girls in the UK. Vaccine 31 (2013), 4961–4967.
19. Blitshteyn, S., Postural tachycardia syndrome following human papillomavirus vaccination. Eur J Neurol 21 (2014), 135–139.
20. Brinth, L.S., Pors, K., Theibel, A.C., Mehlsen, J., Orthostatic intolerance and postural tachycardia syndrome as suspected adverse effects of vaccination against human papilloma virus. Vaccine 33 (2015), 2602–2605.
21. Brinth L, Theibel AC, Pors K, Mehlsen J. Suspected side effects to the quadrivalent human papilloma vaccine. Dan Med J 2015:62.
22. Kinoshita T, Abe RT, Hineno A, Tsunekawa K, Nakane S, Ikeda S. Peripheral sympathetic nerve dysfunction in adolescent Japanese girls following immunization with the human papillomavirus vaccine. Int Med (Tokyo, Jpn) 2014;53:2185–200.
23. Martinez-Lavin, M., Fibromyalgia-like illness in 2 girls after human papillomavirus vaccination. J Clin Rheumatol: Pract Rep Rheumat Musculoskeletal Dis 20 (2014), 392–393.
24. Martinez-Lavin, M., Martinez-Martinez, L.A., Reyes-Loyola, P., HPV vaccination syndrome. A Questionnaire-based study. Clin Rheumatol 34 (2015), 1981–1983.
25. Tomljenovic, L., Colafrancesco, S., Perricone, C., Shoenfeld, Y., Postural Orthostatic tachycardia with chronic fatigue After HPV Vaccination as Part of the “autoimmune/auto-inflammatory syndrome induced by adjuvants”: case report and literature review. J Investigat Med High Impact Case Rep, 2, 2014 2324709614527812.
26. Dahan, S., Tomljenovic, L., Shoenfeld, Y., Postural orthostatic tachycardia syndrome (POTS) – a novel member of the autoimmune family. Lupus 25 (2016), 339–342.
27. Aratani, S., Fujita, H., Kuroiwa, Y., Usui, C., Yokota, S., Nakamura, I., et al. Murine hypothalamic destruction with vascular cell apoptosis subsequent to combined administration of human papilloma virus vaccine and pertussis toxin. Sci Rep, 6, 2016, 36943.
28. Martinez-Lavin, M., Hypothesis: human papillomavirus vaccination syndrome–small fiber neuropathy and dysautonomia could be its underlying pathogenesis. Clin Rheumatol 34 (2015), 1165–1169.
29. European Medicines Agency. Assessment report. Review under Article 20 of Regulation (EC) No 726/2004. Human papillomavirus (HPV) vaccines; 2015. http://www.ema.europa.eu/docs/en_GB/document_library/Referrals_document/HPV_vaccines_20/Opinion_provided_by_Committee_for_Medicinal_Products_for_Human_Use/WC500197129.pdf [accessed 9 Feb 2017].
30. Global Advisory Committee on Vaccine Safety, 2–3 December 2015. Wkly Epidemiol Rec 91 (2016), 21–31.
31. Gøtzsche PC, Jørgensen KJ, Jeffersen T, Auken M, Brinth L. Complaint to the European Medicines Agency (EMA) over maladministration at the EMA; 2016. http://nordic.cochrane.org/sites/nordic.cochrane.org/files/uploads/ResearchHighlights/Complaint-to-EMA-over-EMA.pdf [accessed 9 Feb 2017].
32. Gøtzsche PC, Jørgensen KJ, Jeffersen T, Auken M, Brinth L. Follow-up on our complaint to the European Medicines Agency (EMA) over maladministration at the EMA related to safety of the HPV vaccines; 2016. http://nordic.cochrane.org/sites/nordic.cochrane.org/files/public/uploads/ResearchHighlights/Follow-up-of-complaint-to-EMA.pdf [accessed 9 Feb 2017].
33. Gotzsche, P.C., What do we know about the safety of the HPV vaccines?. Tidsskr Nor Laegeforen 137 (2017), 11–12.
34. Chandler, R.E., Juhlin, K., Fransson, J., Caster, O., Edwards, I.R., Noren, G.N., Current safety concerns with human papillomavirus vaccine: a cluster analysis of reports in vigibase(R). Drug Saf 40 (2017), 81–90.
35. Molbak, K., Hansen, N.D., Valentiner-Branth, P., Pre-vaccination care-seeking in females reporting severe adverse reactions to hpv vaccine. A registry based case-control study. PloS One, 11, 2016, e0162520.
36. Fine, P.E., Chen, R.T., Confounding in studies of adverse reactions to vaccines. Am J Epidemiol 136 (1992), 121–135.
37. De Wals, P., Deceuninck, G., Ouakki, M., Boulianne, N., De Serres, G., Danzig, L., Analysis of mortality following a mass immunization campaign with serogroup C meningococcal conjugate vaccine: methodological difficulties and imperfect solutions. Vaccine 27 (2009), 3223–3227.
38. McCarthy, N.L., Weintraub, E., Vellozzi, C., Duffy, J., Gee, J., Donahue, J.G., et al. Mortality rates and cause-of-death patterns in a vaccinated population. Am J Preven Med 45 (2013), 91–97.
39. Bergsaker M, Feiring B, Hagerup-Jenssen M, Flem E, Stålcrantz J, Wiklund B, et al. Barnevaksinasjonsprogrammet i Norge. Rapport for 2012 [The Norwegian Childhood Immunisation Programme. Report for 2012]. Norwegian Institute of Public Health; 2013. https://www.fhi.no/globalassets/migrering/dokumenter/pdf/barnevaksinasjonsprogrammet-i-norge-rapport-for-2012-pdf.pdf [accessed 24 May 2017, in Norwegian].
40. Norwegian Institute of Public Health. Statistikk for HPV vaksinasjon i barnevaksinasjonsprogrammet [Statistics on HPV vaccination within The Childhood Immunisation Programme]. https://www.fhi.no/hn/helseregistre-og-registre/sysvak/dekkningsstatistikk/. [accessed 24 May 2017, in Norwegian].
41. Bakken, I.J., Tveito, K., Gunnes, N., Ghaderi, S., Stoltenberg, C., Trogstad, L., et al. Two age peaks in the incidence of chronic fatigue syndrome/myalgic encephalomyelitis: a population-based registry study from Norway 2008–2012. BMC Med, 12, 2014, 167.
42. Elgen, I., Hikmat, O., Aspevik, T.N., Hagen, E.M., CFS in children and adolescent: ten years of retrospective clinical evaluation. Int J Pediat, 2013, 2013, 270373.
43. Bakken IJ, Estenstad MG, Gystad SO, Németh J, Huse EH. Nytt norsk pasientregister git nye forskningsmuligheter. Norsk Epidemiol 2010;20:119–24 [in Norwegian].
44. World Health Organization. International statistical classification of diseases and related health problems: ICD-10; 2010. http://apps.who.int/classifications/icd10/browse/2010/en [accessed 24 May 2017].
45. Trogstad L, Ung G, Hagerup-Jenssen M, Cappelen I, Haugen IL, Feiring B. The Norwegian immunisation register – SYSVAK. Euro surveill 2012;17:pii:20147. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20147.
46. The Norwegian Directorate of Health. Nasjonal veileder. Pasienter med CFS/ME: utredning, diagnostikk, behandling, rehabilitering, pleie og omsorg. [National guidelines on CFS/ME]; 2014. https://helsedirektoratet.no/Lists/Publikasjoner/Attachments/396/IS-1944-Nasjonal-Veileder-CFS-ME-Hovedversjon.pdf [accessed 9 Feb 2017, in Norwegian].
47. Norwegian Paediatric Association. Generell veileder i pediatri [Norwegian Paediatric Association, medical guidelines]; 2009. http://www.helsebiblioteket.no/retningslinjer/pediatri/nevrologi/kronisk-utmattelse [accessed 9 Feb 2017, in Norwegian].
48. Fukuda, K., Straus, S.E., Hickie, I., Sharpe, M.C., Dobbins, J.G., Komaroff, A., The chronic fatigue syndrome: a comprehensive approach to its definition and study. International chronic fatigue syndrome study group. Ann Int Med 121 (1994), 953–959.
49. Sulheim, D., Fagermoen, E., Winger, A., Andersen, A.M., Godang, K., Muller, F., et al. Disease mechanisms and clonidine treatment in adolescent chronic fatigue syndrome: a combined cross-sectional and randomized clinical trial. JAMA Pediat 168 (2014), 351–360.
50. Chao, C., Klein, N.P., Velicer, C.M., Sy, L.S., Slezak, J.M., Takhar, H., et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Int Med 271 (2012), 193–203.
51. Klein, N.P., Hansen, J., Chao, C., Velicer, C., Emery, M., Slezak, J., et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediat Adoles Med 166 (2012), 1140–1148.
52. Arnheim-Dahlstrom, L., Pasternak, B., Svanstrom, H., Sparen, P., Hviid, A., Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ (Clin Res Ed), 347, 2013, f5906.
53. Scheller NM, Svanstrom H, Pasternak B, Arnheim-Dahlstrom L, Sundstrom K, Fink K, et al. Quadrivalent HPV vaccination and risk of multiple sclerosis and other demyelinating diseases of the central nervous system. JAMA: J Am Med Assoc 2015;313:54–61.
54. Stillo, M., Carrillo Santisteve, P., Lopalco, P.L., Safety of human papillomavirus vaccines: a review. Expert Opin Drug Safe 14 (2015), 697–712.
55. Vichnin, M., Bonanni, P., Klein, N.P., Garland, S.M., Block, S.L., Kjaer, S.K., et al. An overview of quadrivalent human papillomavirus vaccine safety: 2006 to 2015. Pediat Infect Disease J 34 (2015), 983–991.
56. Schurink-Van't Klooster, T.M., de Ridder, M.A., Kemmeren, J.M., van der Lei, J., Dekker, F., Sturkenboom, M., et al. Examining a possible association between human papilloma virus (HPV) vaccination and migraine: results of a cohort study in the Netherlands. Europ J Pediat 174 (2015), 641–649.
57. Gronlund, O., Herweijer, E., Sundstrom, K., Arnheim-Dahlstrom, L., Incidence of new-onset autoimmune disease in girls and women with pre-existing autoimmune disease after quadrivalent human papillomavirus vaccination: a cohort study. J Int Med 280 (2016), 618–626.
58. Willame, C., Rosillon, D., Zima, J., Angelo, M.G., Stuurman, A.L., Vroling, H., et al. Risk of new onset autoimmune disease in 9- to 25-year-old women exposed to human papillomavirus-16/18 AS04-adjuvanted vaccine in the United Kingdom. Human Vacc Immunotherap 12 (2016), 2862–2871.
59. Aase KA, Stølan J. HPV-vaksinerte norske jenter underøkes for ny sykdom [HPV vaccinated Norwegian girls are investigated for new disease]. Verdens gang; 25 June 2015. http://www.vg.no/nyheter/innenriks/helse-og-medisin/hpv-vaksinerte-norske-jenter-undersoekes-for-ny-sykdom/a/23476511/ [accessed 19 May 2017, in Norwegian].
60. Afari, N., Buchwald, D., Chronic fatigue syndrome: a review. Am J Psychiatry 160 (2003), 221–236.
61. Brinth, L., Pors, K., Hoppe, A.A.G., Badreldin, I., Mehlsen, J., Is chronic fatigue syndrome/myalgic encephalomyelitis a relevant diagnosis in patients with suspected side effects to human papillomavirus virus vaccine?. Int J Vacc Vacc, 1, 2015, 00003.
62. Kanaan, R.A., Lepine, J.P., Wessely, S.C., The association or otherwise of the functional somatic syndromes. Psychosomat Med 69 (2007), 855–859.
63. Henningsen, P., Zipfel, S., Herzog, W., Management of functional somatic syndromes. Lancet 369 (2007), 946–955.
64. Chao, C., Velicer, C., Slezak, J.M., Jacobsen, S.J., Correlates for human papillomavirus vaccination of adolescent girls and young women in a managed care organization. Am J Epidemiol 171 (2010), 357–367.
65. Remes, O., Smith, L.M., Alvarado-Llano, B.E., Colley, L., Levesque, L.E., Individual- and regional-level determinants of human papillomavirus (HPV) vaccine refusal: the Ontario Grade 8 HPV vaccine cohort study. BMC Pub Health, 14, 2014, 1047.
66. Caskey, R., Lindau, S.T., Alexander, G.C., Knowledge and early adoption of the HPV vaccine among girls and young women: results of a national survey. J Adolescent Health: Off Publ Soc Adoles Med 45 (2009), 453–462.
67. Williams, W.W., Lu, P.J., Saraiya, M., Yankey, D., Dorell, C., Rodriguez, J.L., et al. Factors associated with human papillomavirus vaccination among young adult women in the United States. Vaccine 31 (2013), 2937–2946.